Fri, 11 Jan 2019
T cell receptor (TCR) analysis of tumor infiltrating lymphocyte by single-T cell analysis method

Time: 11.00 AM - 12.00 PM

Venue: Cysteine, Level 7 (30 Biopolis Street, Matrix)

Speaker: Dr. Eiji Kobayashi, Assistant Professor, Department of Immunology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Japan


Cancer Immunotherapy is attracting the attention since immune checkpoint inhibitor has demonstrated long-term efficacy in some patients. However, a substantial proportion of patients treated with the checkpoint inhibitors have little or no benefit. Under these situations, T cell receptor (TCR) gene therapy is anticipated as a next generation immunotherapy for cancers.

In this talk, I would like to present our recent results of TCR repertoire analysis of clonally expanded TILs in tumor microenvironment, particularly regarding that of colorectal cancer patients.
To determine TCR repertoire of antigen-specific T cells, various protocols have been developed so far. Comprehensive analyses of the TCR repertoire using next-generation sequencing (NGS) method have recently been reported, however, the NGS analysis is difficult to uniquely determine the TCRα and β pairs of each T cell. Recently, we have established a single-T cell analysis method that enables us to efficiently obtained the antigen-specific TCRs from single T cells and evaluate the TCR function within 10 days, which called hTEC10 (human TCR efficiently cloning within 10 days).

Using hTEC10, we have analyzed TCR repertoire of tumor-infiltrating lymphocytes (TILs) of various cancer patients, and found the clonal T cell populations that expressed the same clonotypic TCR in 50-70% of CD137+CD8+ TILs. We also demonstrated that TCRs from the clonal populations conferred their specificity to tumors.

About The Speaker
Dr. Eiji Kobayashi is the assistant professor of the Department of Immunology, Graduate school of Medicine and Pharmaceutical Sciences, University of Toyama, Japan. He and his colleagues have established an efficient cloning and functional evaluation system of T cell receptors (TCRs) of antigen-specific T cells to obtain TCR-cDNA and determine their antigen-specificity within 10 days.

He also served as a research fellow in Dana-Farber Cancer Institute/Harvard Medical School in US and analyzed influenza-specific T cells from 2014 to 2017. His Lab is currently analyzing tumor infiltrating lymphocytes (TILs) of various types of cancer patients using the system.

He got an award “University of Toyama president award” in 2013. In 2018, he is recognized as one of "the world’s most promising Early Career Investigators" in the Interstellar Initiative organized by the Japan Agency for Medical Research and Development and the New York Academy of Sciences. His scientific interest is now to develop innovative immunotherapies for cancer as well as infectious diseases using antigen-specific TCR genes.

Dr. Samuel Gan, Principal Investigator